Sign in or create account
Search Abstracts and Presentations
Discover Upcoming ASCO Meetings
Benefits of an ASCO Membership
Important Dates
Most Viewed
Videos & Slides
2024 ASCO Annual Meeting
Zanidatamab in previously-treated HER2-positive (HER2+) biliary tract cancer (BTC): Overall survival (OS) and longer follow-up from the phase 2b HERIZON-BTC-01 study.
First Author: Shubham Pant, MD, MBBS
Abstract
2024 ASCO Gastrointestinal Cancers Symposium
Real-world effectiveness and safety of trifluridine-tipiracil (FTD/TPI) and bevacizumab (BEV) in refractory metastatic colorectal cancer (mCRC): The BeTAS trial.
First Author: Nieves Martinez Lago
Poster
2020 ASCO Virtual Scientific Program
TALAPRO-2: a placebo-controlled phase III study of talazoparib (TALA) plus enzalutamide (ENZA) for patients with first-line metastatic castration-resistant prostate cancer (mCRPC).
First Author: Neeraj Agarwal
Journal
JCO Oncology Practice
Results From the ASCO 2019 Survey of Oncology Practice Operations
First Author: Brian Bourbeau